Point-of-Care Glucose Testing Market Trend Analysis And Forecasts to 2033
The global point-of-care glucose testing size was exhibited at USD 3.50 billion in 2023 and is projected to hit around USD 5.33 billion by 2033, growing at a CAGR of 4.3% during the forecast period of 2024 to 2033.
Key Takeaways:
Point-of-Care Glucose Testing Market Report Scope
| Report Coverage | Details |
| Market Size in 2024 | USD 3.50 Billion |
| Market Size by 2033 | USD 5.33 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 4.3% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Product, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | F. Hoffmann-La Roche Ltd.; Abbott; Nipro; PlatInium Equity Advisors, LLC (Lifescan, Inc.); Nova Biomedical; ACON Laboratories; Trividia Health, Inc.; Prodigy Diabetes Care, LLC; Bayer AG/Ascensia Diabetes Care Holdings AG; EKF Diagnostics. |
The growing geriatric population, the ability of point-of-care (POC) diagnostic tests to deliver immediate results, thus providing improved patient care, and rising market penetration of electronic medical records (EMRs) are among the high-impact rendering drivers of this market. The shortage of skilled staff, especially in the field of diagnostics, is also expected to increase the market penetration of glucose POC diagnostic products.
Thus, diabetes management is one of the key priorities among healthcare professionals to limit the mortality rate. According to a survey by the Diabetes Research Foundation, diabetes increases the risk of a fatal outcome by 50% among COVID-19 patients. The growing awareness about diabetes management, poor healthcare access, scarcity of healthcare professionals, and the highest global prevalence recorded in Asian countries are likely to increase the adoption of PoC glucose testing solutions. This, in turn, creates an opportunity to reduce the healthcare burden by improving patient outcomes.
The introduction of favorable regulatory policies aimed at promoting PoC glucose diagnostics is expected to serve as a high impact rendering driver for the market. For example, in the U.S., the implementation of Clinical Laboratory Improvement Amendments (CLIA) is expected to boost usage rates during the forecast period. CLIA-waived tests are approved for use by healthcare providers operating in nontraditional laboratory sites, such as emergency rooms, physician offices, pharmacy clinics, health department clinics, and other healthcare facilities. The prevalence of diabetes is increasing worldwide, which is expanding the patient pool for the market.
Furthermore, the presence of unmet medical needs for diagnosis and management of diabetes and the increase in patient awareness are expected to boost the demand for POC diagnostics. According to the International Diabetes Federation, an estimated 537 million people had diabetes in 2021, and the number is projected to increase to 643 million by 2030 and 783 million by 2045. The healthcare industry is focusing on shorter hospital stays, better acute care, and the expansion of outlying surgical centers, which has consequently increased the demand for Short Turn-Around Testing (STAT). POC management solutions allow patients and healthcare providers to easily collect, share, and manage specimens to meet regulatory requirements.
In March 2023, Astellas Pharma Inc. announced a collaboration with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize the world-renowned Accu-Chek Guide Me blood glucose monitoring system with advanced accuracy as a combined medical product with BlueStar. Welldoc, Inc. created BlueStar, an FDA-cleared digital health solution for diabetes patients that is being offered in the United States and Canada. BlueStar is being developed in Japan by Astellas and Welldoc. Astellas will seek regulatory clearance and reimbursement for a combined medical product in the future.
Product Insights
The others product segment accounted for the largest share of more than 54.6% of the global revenue in 2023 and will continue expanding at a steady CAGR during the forecast period. POC monitoring devices allow home-based self-monitoring of blood glucose levels and help patients perform routine activities with ease. These devices are also being used in inpatient settings as they are easy to use while offering quick results. Several glucose meters have been launched in the industry to suffice the significant need for diabetes monitoring technologies across hospitals, clinics, and other medical settings.
The Accu-Chek Inform II segment held the second-largest share in 2023. The FreeStyle Lite product segment is expected to witness the fastest growth rate over the forecast period. FreeStyle Lite is offered by Abbott and is available in discreet size with an in-built portlight and backlight, which makes it user-friendly for patients with a busy lifestyle. The product is used for measuring blood sugar from samples collected from fingers, forearm, hand, upper arm, and thigh. It is recommended to use the FreeStyle Lite meter only with the FreeStyle control solution and testing strips as the usage of other control solutions and test strips can yield inaccurate results.
Regional Insights
North America dominated the global market in 2023. The regional market accounted for the largest share of over 42.0% of the overall revenue in the same year. It is expected to maintain its lead even during the forecast period. This region is home to several key market players, such as Abbott, Nova Biomedical, and Prodigy Diabetes Care, LLC. This has increased the availability of glucose testing products, thereby contributing to the revenue generation of the regional market. In addition, higher healthcare expenditure by governments on diabetes management is one of the factors responsible for the regional market grow.
The waiver of CLIA for certain POC glucose testing products is the most significant driver of this market. CLIA refers to regulatory standards imposed by the U.S. FDA on all clinical laboratory tests performed on humans except clinical trials and basic research. Asia Pacific is expected to be the most attractive POC diagnostics market owing to the presence of high unmet medical needs and constantly improving healthcare infrastructure in countries witnessing rapid economic development, including India and China.
Furthermore, local manufacturers are continuously evolving in terms of technological advancements and are incorporating latest technologies, such as Picture Archiving and Communication Systems (PACS) and Electronic Medical Records (EMR), which is expected to drive the market growth during the forecast period. Research studies performed on analyzing glucose POC testing compliances offer useful insights for users.
Some of the prominent players in point-of-care glucose testing include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global point-of-care glucose testing.
Product
By Region
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. End Use
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.3.5.1. Data for primary interviews in North America
1.3.5.2. Data for primary interviews in Europe
1.3.5.3. Data for primary interviews in Asia Pacific
1.3.5.4. Data for primary interviews in Latin America
1.3.5.5. Data for Primary interviews in MEA
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Point-of-Care (POC) Glucose Testing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Industry Value Chain Analysis
3.3.1. Reimbursement framework
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.1.1. Introduction of CLIA waived tests
3.4.1.2. Growing prevalence of diabetes
3.4.1.3. Rising demand for short turnaround time glucose POC testing
3.4.2. Market restraint analysis
3.4.2.1. Potential interference and calibration issues in glucose meters
3.4.2.2. Presence of ambiguous regulatory as well as reimbursement framework
3.5. Point-of-Care(POC) Glucose Testing Market Analysis Tools
3.5.1. Industry Analysis - Porter’s
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic landscape
3.5.3. Major Deals & Strategic Alliances Analysis
3.5.4. Market Entry Strategies
Chapter 4. Point-of-Care (POC) Glucose Testing Market: Product Estimates & Trend Analysis
4.1. Definitions and Scope
4.1.1. Accu-Check Aviva Meter
4.1.2. Onetouch Verio Flex
4.1.3. i-STAT
4.1.4. Freestyle Lite
4.1.5. Bayer CONTOUR Blood Glucose Monitoring System
4.1.6. True Metrix
4.1.7. Accu-Check Inform II
4.1.8. StatStrip
4.1.9. Others
4.2. Product Market Share, 2024 & 2033
4.3. Segment Dashboard
4.4. Point-of-Care (POC) Glucose Testing Market by Product Outlook
4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2030 for the following
4.5.1. Accu-Check Aviva Meter
4.5.1.1. Accu-Check Aviva Meter market estimates and forecast, 2021 - 2033
4.5.2. Onetouch Verio Flex
4.5.2.1. Onetouch Verio Flex market estimates and forecast, 2021 - 2033
4.5.3. i-STAT
4.5.3.1. I-STAT market estimates and forecast, 2021 - 2033
4.5.4. Freestyle Lite
4.5.4.1. Freestyle Lite market estimates and forecast, 2021 - 2033
4.5.5. Bayer CONTOUR Blood Glucose Monitoring System
4.5.5.1. Bayer CONTOUR Blood Glucose Monitoring System market estimates and forecast, 2021 - 2033
4.5.6. True Metrix
4.5.6.1. True Metrix market estimates and forecast, 2021 - 2033
4.5.7. Accu-Check Inform II
4.5.7.1. Accu-Check Inform II market estimates and forecast, 2021 - 2033
4.5.8. StatStrip
4.5.8.1. StatStrip market estimates and forecast, 2021 - 2033
4.5.9. Others
4.5.9.1. Others market estimates and forecast, 2021 - 2033
Chapter 5. Point-of-Care (POC) Glucose Testing Market: Regional Estimates & Trend Analysis
5.1. Regional market share analysis, 2024 & 2033
5.2. Regional Marketplace: Key Takeaways
5.3. North America
5.3.1. SWOT Analysis
5.3.2. Market estimates and forecast, 2016-2030 (Revenue, USD Million)
5.3.3. U.S.
5.3.3.1. Country Dynamics
5.3.3.2. Country Variables
5.3.3.3. Competitive Landscape
5.3.3.4. Regulatory/Reimbursement Framework
5.3.3.5. Market estimates and forecast, 2021 - 2033
5.3.4. Canada
5.3.4.1. Country Dynamics
5.3.4.2. Country Variables
5.3.4.3. Competitive Landscape
5.3.4.4. Regulatory/Reimbursement Framework
5.3.4.5. Market estimates and forecast, 2021 - 2033
5.4. Europe
5.4.1. SWOT Analysis
5.4.2. Market estimates and forecast, 2021 - 2033
5.4.3. UK
5.4.3.1. Country Dynamics
5.4.3.2. Country Variables
5.4.3.3. Competitive Landscape
5.4.3.4. Regulatory/Reimbursement Framework
5.4.3.5. Market estimates and forecast, 2021 - 2033
5.4.4. Germany
5.4.4.1. Country Dynamics
5.4.4.2. Country Variables
5.4.4.3. Competitive Landscape
5.4.4.4. Regulatory/Reimbursement Framework
5.4.4.5. Market estimates and forecast, 2021 - 2033
5.4.5. France
5.4.5.1. Country Dynamics
5.4.5.2. Country Variables
5.4.5.3. Competitive Landscape
5.4.5.4. Regulatory/Reimbursement Framework
5.4.5.5. Market estimates and forecast, 2021 - 2033
5.4.6. Italy
5.4.6.1. Country Dynamics
5.4.6.2. Country Variables
5.4.6.3. Competitive Landscape
5.4.6.4. Regulatory/Reimbursement Framework
5.4.6.5. Market estimates and forecast, 2021 - 2033
5.4.7. Spain
5.4.7.1. Country Dynamics
5.4.7.2. Country Variables
5.4.7.3. Competitive Landscape
5.4.7.4. Regulatory/Reimbursement Framework
5.4.7.5. Market estimates and forecast, 2021 - 2033
5.4.8. Denmark
5.4.8.1. Country Dynamics
5.4.8.2. Country Variables
5.4.8.3. Competitive Landscape
5.4.8.4. Regulatory/Reimbursement Framework
5.4.8.5. Market estimates and forecast, 2021 - 2033
5.4.9. Sweden
5.4.9.1. Country Dynamics
5.4.9.2. Country Variables
5.4.9.3. Competitive Landscape
5.4.9.4. Regulatory/Reimbursement Framework
5.4.9.5. Market estimates and forecast, 2021 - 2033
5.4.10. Norway
5.4.10.1. Country Dynamics
5.4.10.2. Country Variables
5.4.10.3. Competitive Landscape
5.4.10.4. Regulatory/Reimbursement Framework
5.4.10.5. Market estimates and forecast, 2021 - 2033
5.5. Asia Pacific
5.5.1. SWOT Analysis
5.5.2. Market estimates and forecast, 2021 - 2033
5.5.3. Japan
5.5.3.1. Country Dynamics
5.5.3.2. Country Variables
5.5.3.3. Competitive Landscape
5.5.3.4. Regulatory/Reimbursement Framework
5.5.3.5. Market estimates and forecast, 2021 - 2033
5.5.4. China
5.5.4.1. Country Dynamics
5.5.4.2. Country Variables
5.5.4.3. Competitive Landscape
5.5.4.4. Regulatory/Reimbursement Framework
5.5.4.5. Market estimates and forecast, 2021 - 2033
5.5.5. India
5.5.5.1. Country Dynamics
5.5.5.2. Country Variables
5.5.5.3. Competitive Landscape
5.5.5.4. Regulatory/Reimbursement Framework
5.5.5.5. Market estimates and forecast, 2021 - 2033
5.5.6. Australia
5.5.6.1. Country Dynamics
5.5.6.2. Country Variables
5.5.6.3. Competitive Landscape
5.5.6.4. Regulatory/Reimbursement Framework
5.5.6.5. Market estimates and forecast, 2021 - 2033
5.5.7. Thailand
5.5.7.1. Country Dynamics
5.5.7.2. Country Variables
5.5.7.3. Competitive Landscape
5.5.7.4. Regulatory/Reimbursement Framework
5.5.7.5. Market estimates and forecast, 2021 - 2033
5.5.8. South Korea
5.5.8.1. Country Dynamics
5.5.8.2. Country Variables
5.5.8.3. Competitive Landscape
5.5.8.4. Regulatory/Reimbursement Framework
5.5.8.5. Market estimates and forecast, 2021 - 2033
5.6. Latin America
5.6.1. SWOT Analysis
5.6.2. Market estimates and forecast, 2021 - 2033
5.6.3. Brazil
5.6.3.1. Country Dynamics
5.6.3.2. Country Variables
5.6.3.3. Competitive Landscape
5.6.3.4. Regulatory/Reimbursement Framework
5.6.3.5. Market estimates and forecast, 2021 - 2033
5.6.4. Mexico
5.6.4.1. Country Dynamics
5.6.4.2. Country Variables
5.6.4.3. Competitive Landscape
5.6.4.4. Regulatory/Reimbursement Framework
5.6.4.5. Market estimates and forecast, 2021 - 2033
5.6.5. Argentina
5.6.5.1. Country Dynamics
5.6.5.2. Country Variables
5.6.5.3. Competitive Landscape
5.6.5.4. Regulatory/Reimbursement Framework
5.6.5.5. Market estimates and forecast, 2021 - 2033
5.7. MEA
5.7.1. SWOT Analysis
5.7.2. Market estimates and forecast, 2021 - 2033
5.7.3. South Africa
5.7.3.1. Country Dynamics
5.7.3.2. Country Variables
5.7.3.3. Competitive Landscape
5.7.3.4. Regulatory/Reimbursement Framework
5.7.3.5. Market estimates and forecast, 2021 - 2033
5.7.4. Saudi Arabia
5.7.4.1. Country Dynamics
5.7.4.2. Country Variables
5.7.4.3. Competitive Landscape
5.7.4.4. Regulatory/Reimbursement Framework
5.7.4.5. Market estimates and forecast, 2021 - 2033
5.7.5. UAE
5.7.5.1. Country Dynamics
5.7.5.2. Country Variables
5.7.5.3. Competitive Landscape
5.7.5.4. Regulatory/Reimbursement Framework
5.7.5.5. Market estimates and forecast, 2021 - 2033
5.7.6. Kuwait
5.7.6.1. Country Dynamics
5.7.6.2. Country Variables
5.7.6.3. Competitive Landscape
5.7.6.4. Regulatory/Reimbursement Framework
5.7.6.5. Market estimates and forecast, 2021 - 2033
Chapter 6. Competitive Landscape
6.1. Recent Developments & Impact Analysis, By Key Market Participants
6.2. Company/Competition Categorization
6.2.1. Innovators
6.3. Vendor Landscape
6.3.1. List of key distributors and channel partners
6.3.2. Key customers
6.3.3. Key company market share analysis, 2022
6.3.4. F. Hoffmann-La Roche Ltd.
6.3.4.1. Company overview
6.3.4.2. Financial performance
6.3.4.3. Product benchmarking
6.3.4.4. Strategic initiatives
6.3.5. Abbott
6.3.5.1. Company overview
6.3.5.2. Financial performance
6.3.5.3. Product benchmarking
6.3.5.4. Strategic initiatives
6.3.6. Nipro
6.3.6.1. Company overview
6.3.6.2. Financial performance
6.3.6.3. Product benchmarking
6.3.6.4. Strategic initiatives
6.3.7. PlatInium Equity Advisors, LLC (Lifescan, Inc.)
6.3.7.1. Company overview
6.3.7.2. Financial performance
6.3.7.3. Product benchmarking
6.3.7.4. Strategic initiatives
6.3.8. Nova Biomedical
6.3.8.1. Company overview
6.3.8.2. Financial performance
6.3.8.3. Product benchmarking
6.3.8.4. Strategic initiatives
6.3.9. ACON Laboratories
6.3.9.1. Company overview
6.3.9.2. Financial performance
6.3.9.3. Product benchmarking
6.3.9.4. Strategic initiatives
6.3.10. Trividia Health, Inc.
6.3.10.1. Company overview
6.3.10.2. Financial performance
6.3.10.3. Product benchmarking
6.3.10.4. Strategic initiatives
6.3.11. Prodigy Diabetes Care, LLC
6.3.11.1. Company overview
6.3.11.2. Financial performance
6.3.11.3. Product benchmarking
6.3.11.4. Strategic initiatives
6.3.12. Bayer AG/Ascensia Diabetes Care Holdings AG
6.3.12.1. Company overview
6.3.12.2. Financial performance
6.3.12.3. Product benchmarking
6.3.12.4. Strategic initiatives
6.3.13. EKF Diagnostics
6.3.13.1. Company overview
6.3.13.2. Financial performance
6.3.13.3. Product benchmarking
6.3.13.4. Strategic initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers